Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Union Pacific Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Union Pacific Corporation trades at $287.74 (market cap $170.37B). The key difference: Union Pacific Corporation is far larger — about 4.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Union Pacific Corporation pays a 1.92% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UNP | |
|---|---|---|
Market Cap | $39.89B | $170.37B |
Sector | Health | Industrials |
52-Week High | $491.22 | $286.96 |
52-Week Low | $278.09 | $214.91 |
Enterprise Value | $38.15B | $200.84B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Union Pacific (UNP) trades at $286.96, up 0.67% today, with strong technical momentum indicated by bullish moving averages. The company maintains robust fundamentals with a 29.2% net income margin and consistent earnings beats in recent quarters. Key developments include the proposed $85 billion merger with Norfolk Southern, though regulatory scrutiny remains. Cash flow from operations remains healthy at $9.29 billion for 2025, supporting dividend payments and strategic initiatives.
Outlook remains positive with analyst consensus targeting $296.27, though risks include merger approval uncertainties and a class-action lawsuit. The stock's current valuation at 23.62 P/E reflects premium pricing, requiring sustained earnings growth to justify further upside. Near-term focus is on Q2 2026 earnings release scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
